EWTX CFO receives 262,500 options and 43,750 RSUs in 2025

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. (EWTX) reported new equity awards to its Chief Financial Officer, Michael Nofi. On 11/10/2025, he received 43,750 restricted stock units (RSUs) that convert into the same number of common shares, vesting in four equal annual installments beginning on November 10, 2026. He was also granted stock options to purchase 262,500 shares of common stock at an exercise price of $18.28 per share. One quarter of these options vest on November 10, 2026, and the remaining options vest in equal monthly installments over the following three years, contingent on his continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nofi Michael

(Last) (First) (Middle)

1715 38TH STREET

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0.00	11/10/2025		A		43,750		(1)	11/10/2035	Common Stock	43,750	$0.00	43,750	D
Stock Options (Right to buy)	$18.28	11/10/2025		A		262,500		(2)	11/10/2035	Common Stock	262,500	$0.00	262,500	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on November 10, 2026.

2. 1/4th of the shares subject to the option become vested and exercisable on November 10, 2026 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

	/s/ John R. Moore, Attorney-in-Fact for Michael Nofi	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Edgewise Therapeutics (EWTX) grant to its CFO?

Edgewise Therapeutics granted its CFO 43,750 restricted stock units (RSUs) and stock options for 262,500 shares of common stock at an exercise price of $18.28 per share.

How do the new RSUs for the Edgewise Therapeutics CFO vest?

The 43,750 RSUs vest in four equal annual installments, with the first installment vesting on November 10, 2026, and each vested RSU entitles the holder to one share of common stock.

What is the vesting schedule for the 262,500 stock options at Edgewise Therapeutics?

For the 262,500 stock options, 1/4 of the shares vest and become exercisable on November 10, 2026, and 1/48 of the shares continue to vest each month thereafter, subject to the CFO continuing as a service provider.

What is the exercise price of the new Edgewise Therapeutics stock options?

The newly granted stock options to the CFO have an exercise price of $18.28 per share of Edgewise Therapeutics common stock.

Who is the reporting person in this Edgewise Therapeutics Form 4 filing?

The reporting person is Michael Nofi, who serves as the Chief Financial Officer of Edgewise Therapeutics, Inc.

What is the transaction date reported in this Edgewise Therapeutics Form 4?

The earliest transaction date reported for the equity awards to the CFO is 11/10/2025.